Zalicus Initiates Phase 1 Clinical Trial of Z944

Zalicus Inc.

a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of Z944, a novel oral T-type calcium channel blocker with demonstrated preclinical potential for the treatment of acute and inflammatory pain. In addition, Zalicus has drawn the remaining $8.5 million from its $20.0 million secured credit facility with Oxford Finance to fund ion channel clinical development.